Topics

Mallinckrodt drug shows benefit in rare liver, kidney disease

13:14 EDT 15 Aug 2019 | MedCity News

Paper made silhouettes with one of them of orange color to stand out from the rest

The drugmaker reported top-line data from its Phase III study of terlipressin in hepatorenal syndrome type 1, or HSR-1, a disease with no drug treatment available in the U.S. or Canada that affects 30,000-40,000 people per year.

Original Article: Mallinckrodt drug shows benefit in rare liver, kidney disease

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt drug shows benefit in rare liver, kidney disease"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...